ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$2.47 USD
+0.18 (7.86%)
Updated Jul 11, 2024 03:52 PM ET
After-Market: $2.46 -0.01 (-0.40%) 7:24 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for ASLAN Pharmaceuticals Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 21 | 57 | 90 | 14 | 22 |
Receivables | 0 | 0 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 4 | 4 | 1 | 0 |
Total Current Assets | 24 | 61 | 94 | 16 | 22 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 25 | 61 | 95 | 16 | 23 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 13 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 2 | 8 | 0 | 4 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 2 | 3 | 5 | 3 |
Total Current Liabilities | 13 | 23 | 6 | 11 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 25 | 30 | 31 | 15 | 18 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 53 | 37 | 26 | 24 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 64 | 63 | 63 | 62 | 61 |
Capital Surplus | 244 | 224 | 221 | 124 | 117 |
Retained Earnings | -321 | -278 | -227 | -196 | -179 |
Other Equity | 0 | 0 | 0 | 0 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -13 | 8 | 57 | -10 | -1 |
Total Liabilities & Shareholder's Equity | 25 | 61 | 95 | 16 | 23 |
Total Common Equity | -13 | 8 | 57 | -10 | -1 |
Shares Outstanding | 2.00 | 1.70 | 1.70 | 0.80 | 0.80 |
Book Value Per Share | -6.65 | 4.92 | 33.71 | -12.69 | -0.75 |
Fiscal Year End for ASLAN Pharmaceuticals Ltd falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 18 | 21 | 41 | 41 |
Receivables | NA | 0 | 0 | 0 | 12 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 3 | 3 | 2 |
Total Current Assets | NA | 21 | 24 | 44 | 55 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 21 | 25 | 45 | 55 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 10 | 8 | 4 | 6 |
Current Portion Long-Term Debt | NA | 7 | 2 | 13 | 13 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 3 | 3 | 5 |
Total Current Liabilities | NA | 20 | 13 | 21 | 24 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 19 | 25 | 25 | 24 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 39 | 38 | 46 | 49 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 65 | 64 | 64 | 64 |
Capital Surplus | NA | 248 | 244 | 245 | 242 |
Retained Earnings | NA | -331 | -321 | -309 | -299 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -18 | -13 | -1 | 6 |
Total Liabilities & Shareholder's Equity | NA | 21 | 25 | 45 | 55 |
Total Common Equity | 0 | -18 | -13 | -1 | 6 |
Shares Outstanding | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Book Value Per Share | 0.00 | -8.98 | -6.65 | -0.44 | 3.19 |